MDWD MediWound Ltd.
USHealthcareAs of 2026-07-08 16:00
Why MDWD matters now
MediWound Ltd. (MDWD) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.70 with -1.61% on the session and $159.7M in market capitalization; recent performance reads 1-month -14.63% and YTD -22.86%.
The latest financial table shown here is Q1 2026, with revenue of $1.5M, net income of $-3.0M, and EPS of $-0.23. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -15.7%.
The latest indexable market news headline is "MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $27.00; recent insider activity includes SHAMIR NACHUM filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.43
P/S
10.68
EV/EBITDA
-7.96
DCF Value
$-26.27
FCF Yield
-15.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
19.6%
Operating Margin
-193.6%
Net Margin
-180.3%
ROE
-67.2%
ROA
-32.6%
ROIC
-47.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.5M | $-3.0M | $-0.23 |
| Q4 2025 | $1.9M | $-7.2M | $-0.56 |
| FY 2025 | $17.0M | $-23.9M | $-2.10 |
| Q3 2025 | $5.4M | $-2.7M | $-0.24 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$27.00
Target (Median)
$27.00
Target Range
$22.00 - $32.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IL
Exchange
—
Beta
0.15
MediWound Ltd., an Israeli biopharmaceutical company established in 2000 and based in Yavne, focuses on the innovation, production, and sale of advanced biological treatments for the healing and regrowth of damaged tissues. The company's key commercialized product is NexoBrid, a biological drug distributed to specialized burn centers and hospital burn units. NexoBrid is specifically formulated for the enzymatic debridement of eschar—dead or compromised tissue—in adults suffering from severe thermal burns, encompassing deep partial-thickness and full-thickness injuries. Furthermore, MediWound's development pipeline includes EscharEx, which has successfully concluded Phase II clinical trials for addressing chronic and other intractable wounds. Another investigational therapy, MW005, is currently undergoing Phase I/II clinical studies for the treatment of low-risk basal cell carcinoma.